Edition:
United States

Genomic Health Inc (GHDX.O)

GHDX.O on Nasdaq

32.45USD
20 Feb 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$32.45
Open
$32.70
Day's High
$33.39
Day's Low
$32.24
Volume
250,835
Avg. Vol
168,254
52-wk High
$37.50
52-wk Low
$26.54

Latest Key Developments (Source: Significant Developments)

Genomic Health Announces Research Collaboration with Janssen Pharma
Wednesday, 6 Dec 2017 08:00am EST 

Dec 6 (Reuters) - Genomic Health Inc ::GENOMIC HEALTH ANNOUNCES RESEARCH COLLABORATION WITH JANSSEN PHARMACEUTICALS TO EVALUATE THE ONCOTYPE DX® GENOMIC PROSTATE SCORE™ TEST FOR POTENTIAL DRUG DEVELOPMENT.GENOMIC HEALTH - AS PER AGREEMENT, CO WILL TEST SAMPLES FROM JANSSEN STUDIES TO EXAMINE ASSOCIATION OF GENOMIC PROSTATE SCORE RESULTS WITH CLINICAL OUTCOMES.  Full Article

Genomic Health And Cleveland Diagnostics Announce Strategic Collaboration To Develop And Commercialize New Prostate Cancer Tests
Tuesday, 28 Nov 2017 08:00am EST 

Nov 28 (Reuters) - Genomic Health Inc ::GENOMIC HEALTH AND CLEVELAND DIAGNOSTICS ANNOUNCE STRATEGIC COLLABORATION TO DEVELOP AND COMMERCIALIZE NEW PROSTATE CANCER TESTS.GENOMIC HEALTH-DEAL TO PROVIDE CO WITH EXCLUSIVE GLOBAL RIGHTS TO DEVELOP CANCER TESTS BASED ON CLEVELAND DIAGNOSTICS' ISOPSA REAGENT & SIA TECHNOLOGY​.GENOMIC HEALTH INC - ‍GENOMIC HEALTH IS EXPECTED TO BEGIN ADDITIONAL DEVELOPMENT AND CLINICAL VALIDATION OF FIRST HIGH-PSA REFLEX TEST IN 2018​.GENOMIC HEALTH INC - ‍GENOMIC HEALTH WILL MAKE A CONVERTIBLE NOTE INVESTMENT IN CLEVELAND DIAGNOSTICS IN PRINCIPAL AMOUNT OF $2 MILLION IN Q4 OF 2017​.  Full Article

Genomic Health Q3 loss per share $0.06
Wednesday, 8 Nov 2017 04:05pm EST 

Nov 8 (Reuters) - Genomic Health Inc ::Genomic Health announces third quarter 2017 financial results and reports recent business progress.Q3 loss per share $0.06.Q3 revenue $83.8 million versus I/B/E/S view $86.9 million.Q3 earnings per share view $-0.03 -- Thomson Reuters I/B/E/S.Genomic Health - ‍expects to meet low end of FY revenue guidance, which is $345 million, excluding estimated hurricane impact on revenue of about $3 million in Q3​.Genomic Health Inc - ‍expects to deliver full-year profit, excluding $3.2 million cost of biocartis transaction​.  Full Article

Genomic Health and Biocartis announce agreement to develop a breast cancer test
Wednesday, 13 Sep 2017 01:00am EDT 

Sept 13 (Reuters) - BIOCARTIS GROUP NV ::‍GENOMIC HEALTH AND BIOCARTIS ANNOUNCE AGREEMENT TO DEVELOP AN IDYLLA(TM) IVD ONCOTYPE DX(®) BREAST CANCER TEST TO BROADEN GLOBAL PATIENT ACCESS​.‍EXCLUSIVE AGREEMENT TO DEVELOP AN IVD VERSION OF ONCOTYPE DX BREAST RECURRENCE SCORE TEST ON BIOCARTIS' IDYLLA PLATFORM​.‍ONCOTYPE DX BREAST RECURRENCE SCORE TEST PLANNED FOR LAUNCH IN EUROPE BEGINNING WITH FRANCE AND GERMANY IN 2019​.‍AS PART OF AGREEMENT, GENOMIC HEALTH WILL MAKE A PAYMENT OF APPROXIMATELY $3.3 MILLION TO BIOCARTIS, WHICH IS EXPECTED TO BE EXPENSED IN Q3 OF 2017​.‍GENOMIC HEALTH CONTINUES TO EXPECT TO BE PROFITABLE FOR FULL YEAR 2017, EXCLUDING THESE TRANSACTION COSTS​.‍UPON COMMERCIALIZATION, GENOMIC HEALTH WILL MAKE ROYALTY PAYMENTS TO BIOCARTIS BASED ON NET SALES OF IVD TESTS DEVELOPED ON BIOCARTIS' IDYLLA PLATFORM​.  Full Article

Palmetto GBA issues positive final local coverage determination to expand medicare coverage of Oncotype DX genomic prostate score test
Thursday, 24 Aug 2017 08:00am EDT 

Aug 24 (Reuters) - Genomic Health Inc :Palmetto GBA issued positive final local coverage determination to expand medicare coverage of Oncotype DX genomic prostate score test.  Full Article

Genomic Health Q2 loss per share $0.08
Tuesday, 1 Aug 2017 04:05pm EDT 

Aug 1 (Reuters) - Genomic Health Inc :Genomic Health announces second quarter 2017 financial results and reports recent business progress.Q2 loss per share $0.08.Q2 revenue $85.5 million versus I/B/E/S view $86.1 million.Q2 earnings per share view $-0.06 -- Thomson Reuters I/B/E/S.Sees 2017 total revenue of between $345 to $355 million.Sees profit for full-year at either end of revenue range.FY2017 earnings per share view $0.02, revenue view $356.1 million -- Thomson Reuters I/B/E/S.  Full Article

Genomic Health Q1 revenue $84 million
Tuesday, 9 May 2017 04:05pm EDT 

May 9 (Reuters) - Genomic Health Inc ::Genomic Health announces first quarter 2017 financial results and reports recent business progress.Q1 loss per share $0.02.Q1 revenue $84 million versus I/B/E/S view $86.2 million.Q1 earnings per share view $-0.06 -- Thomson Reuters I/B/E/S.Says international product revenue was $13.4 million in Q1 of 2017, compared with $10.4 million in Q1 of 2016.Says U.S. product revenue was $70.6 million in Q1 of 2017, compared with $70.5 million in Q1 of 2016.  Full Article

Genomic Health says may sell up to 13.7 mln shares
Thursday, 11 Aug 2016 05:34pm EDT 

Genomic Health Inc : Says may sell up to an aggregate of 13.7 million shares of common stock - SEC filing .Shares being offered by selling stockholders, co will not receive any proceeds from the sale.  Full Article

Genomic Health files for mixed shelf of up to $350 mln - SEC filing
Thursday, 11 Aug 2016 04:15pm EDT 

Genomic Health Inc : Files for mixed shelf of up to $350 million - SEC filing Source: (http://bit.ly/2b0l97v ) Further company coverage: [GHDX.O] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

Genomic Health posts Q2 loss per share $0.18
Tuesday, 2 Aug 2016 04:05pm EDT 

Genomic Health Inc : Q2 loss per share $0.18 . Q2 revenue $82 million versus $70.6 million . Is raising low end of both revenue and test guidance for full-year ending December 31, 2016 . Maintaining net loss guidance between $12 and $18 million at mid-point of revenue guidance, excluding items for 2016 . FY2016 earnings per share view $-0.45, revenue view $330.3 million -- Thomson Reuters I/B/E/S . Q2 earnings per share view $-0.18, revenue view $81.3 million -- Thomson Reuters I/B/E/S . Raising total revenue to between $325 and $335 million for 2016 .Sees 2016 basic net loss per share of between $0.37 and $0.55.  Full Article

BRIEF-Genomic Health - Oncotype DX Genomic Prostate Score™ Test Increases Use Of Active Surveillance

* ONCOTYPE DX® GENOMIC PROSTATE SCORE™ TEST INCREASES USE OF ACTIVE SURVEILLANCE BY 30 PERCENT IN LOW-RISK PATIENTS, RESULTING IN GREATER ADHERENCE TO GUIDELINE-BASED CARE Source text for Eikon: Further company coverage: